Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
The Cochrane Database of Systematic Reviews|May 14, 2010
Drug-eluting stents versus bare metal stents for angina or acute coronary syndromesJanette Greenhalgh, Juliet Hockenhull, Naveen Rao, et al.
Pharmacoeconomics|June 28, 2006
A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategiesAdrian Bagust, Marc Evans, Sophie Beale, et al.
Pharmacoepidemiology and Drug Safety|September 30, 2003
Using disease registries for pharmacoepidemiological research: a case study of data from a cystic fibrosis registryJudith Strobl, Ian Enzer, Adrian Bagust, et al.
Pharmacoeconomics|August 21, 2014
Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancerNigel Fleeman, Adrian Bagust, Sophie Beale, et al.
Thorax|February 9, 2007
Population screening for lung cancer using computed tomography, is there evidence of clinical effectiveness? A systematic review of the literatureCorri Black, Robyn de Verteuil, Shonagh Walker, et al.
Pharmacoeconomics|June 28, 2006
Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in SpainArran T Shearer, Adrian Bagust, F Javier Ampudia-Blasco, et al.
Pharmacoeconomics|October 12, 2013
Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisalSophie Beale, Rumona Dickson, Adrian Bagust, et al.
Pharmacoeconomics|May 15, 2010
Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisalAdrian Bagust, Janette Greenhalgh, Angela Boland, et al.
Pharmacoeconomics - Open|February 12, 2019
Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology AppraisalNigel Fleeman, Adrian Bagust, Rui Duarte, et al.
Pharmacoeconomics|April 24, 2015
Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group PerspectiveNigel Fleeman, Adrian Bagust, Sophie Beale, et al.
Pageof 3